Six open questions

Everything else from the audit is applied. Enter hub password to continue.

That's not right. Try again.

Decisions needed · 29 July 2026

testosteroneinwomen.com, six open questions

Every other finding from the audit is applied and live. These six need a fact or a judgment call only you can make. Each one has verified citations and my recommendation, so most of them should take under a minute.

Already applied, no action needed: 70 edits across all thirteen documents.

All six emails now pass the linter clean, including the fabricated reader testimonial (gone), the dangling "those bodies" sentence (replaced with a sourced Grade A statement), and the duplicated sign-off in email 06. The 97 dashes in anhedonia-testosterone-midlife.md are gone, including the one in the Google description. All four broken citation page ranges are repaired, and the sentence whose meaning the old sweep reversed is fixed. Both faux-insight headings on who-will-prescribe-it are plain again, and the SHBG caveat from your own source notes is now in the body of why-are-my-labs-normal.

Full detail: the audit page.

1. The Black women sentence

Both anhedonia articles · left untouched in both, byte for byte

Currently: "In psychiatry, anhedonia in Black patients is systematically undertreated, studies consistently show Black women are less likely to have their mood symptoms taken seriously and more likely to have them attributed to external circumstances rather than biology."

I found strong citations for part of this and none at all for the rest. The undertreatment half is very well evidenced. The "attributed to external circumstances rather than biology" half I could not source anywhere, and the literature actually documents the opposite mechanism: Black patients' mood symptoms get reclassified as psychosis, which is a different and frankly more striking finding. There's also no anhedonia-specific disparity literature at all, and one large study found the PHQ-9 anhedonia item works the same across racial groups.

Verified citations, all confirmed at CrossRef:

[Alegría M, et al. *Psychiatr Serv.* 2008;59(11):1264-1272. doi:10.1176/ps.2008.59.11.1264]

[González HM, et al. *Arch Gen Psychiatry.* 2010;67(1):37-46. doi:10.1001/archgenpsychiatry.2009.168]

[Cook BL, et al. *Psychiatr Serv.* 2017;68(1):9-16. doi:10.1176/appi.ps.201500453]

[Gara MA, et al. *Arch Gen Psychiatry.* 2012;69(6):593-600. doi:10.1001/archgenpsychiatry.2011.2040]

[Olbert CM, Nagendra A, Buck B. *J Abnorm Psychol.* 2018;127(1):104-115. doi:10.1037/abn0000309]

[Blanken A, et al. *Menopause.* 2022;29(7):877-882. doi:10.1097/GME.0000000000001978]

What they found: Alegría, 8,762 US adults, 58.8% of African Americans with past-year depression got no treatment at all versus 40.2% of white adults. González, 15,762 adults, lower odds of guideline-concordant care despite no significant difference in depression severity between groups. Cook, 214,597 adults, the gap widened from 8.2% to 10.8% between 2004 and 2012. Gara, 610 patients with race-blinded expert diagnosis as the comparator, African American patients had 2.7 times the odds of a clinical schizophrenia diagnosis with no greater severity of depressive or manic symptoms. Olbert, meta-analysis of 55 studies, 2.42-fold schizophrenia diagnostic disparity. Blanken is the one women-only cohort, 200,901 women veterans aged 45 to 64, Black women less likely to have menopause symptoms documented at all and 26% less likely to be prescribed hormone therapy. Blanken is already in your ResearchLibrary with status: fulltext.

Recommended

Replace the passage with this, which is fully sourced and a stronger point than the original:

"Depression in Black patients is systematically undertreated. In nationally representative samples, roughly 59% of African Americans with a past-year depressive disorder received no mental health care at all, compared with 40% of white adults, and that gap widened rather than closed through 2012. When Black patients do reach a clinician, their mood symptoms are more likely to be recoded than treated: in studies using race-blinded expert diagnosis as the comparator, African American patients were nearly three times as likely to be clinically diagnosed with schizophrenia despite showing no greater severity of depressive or manic symptoms. For midlife women the same pattern shows up in menopause care, where Black women veterans were less likely to have their symptoms documented at all and 26% less likely to be prescribed systemic hormone therapy."

Or: if the "external circumstances" framing came from something you read, send me the source and I'll verify it and keep your original sentence.

Either way, drop the word "anhedonia" from the race sentence. The disparity evidence is about depression and mood disorders generally, and stretching it to anhedonia specifically is the one part a hostile reader could break.

2. "Androgen effects commonly take three to six months"

do-i-need-it.md line 146 · left untouched

No verifiable source says exactly "three to six months." The British Menopause Society clinician tool does say 3 to 6 months, but it's a society PDF with no DOI, which fails your own citation bar. What is fully sourced is a six-month floor, and it makes a sharper criticism than the original.

[Davis SR, et al. *J Sex Med.* 2019;16(9):1331-1337. doi:10.1016/j.jsxm.2019.07.012]

[Davis SR, et al. *N Engl J Med.* 2008;359(19):2005-2017. doi:10.1056/NEJMoa0707302]

[Scott A, Newson L. *Br J Gen Pract.* 2020;70(693):203-204. doi:10.3399/bjgp20X709265]

The 2019 Global Consensus recommendation 8h says verbatim: "If no benefit is experienced by 6 months, treatment should be ceased (Level IB, Grade C)." Its own evidence base only admitted blinded RCTs of at least 12 weeks. APHRODITE, the pivotal trial, n=814, measured its primary endpoint at week 24. The BJGP prescribing guide tells GPs it can take months and not to judge before six.

Recommended

"Eight weeks. The trial ran less than the twelve-week minimum the global consensus required just to include a study in its evidence base, and less than half the twenty-four weeks the pivotal testosterone trial used to measure its primary endpoint. That same consensus tells clinicians not to call testosterone a failure until six months have passed."

Or: keep your sentence and cite the BMS tool as a non-DOI source, if you're comfortable with that exception.

3. The pharmacy chains claim

who-will-prescribe-it.md line 63 · left untouched

Currently: "Some pharmacy chains apply extra scrutiny to off-label testosterone for women as a matter of policy."

This states a policy claim about named commercial actors, anonymously, on a page that promises everything is cited. I'm proposing no replacement text because every honest fix needs a fact I don't have. Three routes:

If your research file names the chains and the policies are documented, name them.
Cut the sentence. The Schedule III bullet stands on its own without it.
If it comes from patient reports rather than published policy, say that in the sentence.

Recommended the third one, if that's where it came from. "Women report extra scrutiny at some chain pharmacies" is honest, useful, and needs no citation.

4. The R-squared number, and this one is new

testosterone-women.md line 139 · left untouched, and it's the reason I left the sentence around it alone too

This surfaced during citation checking, not in the original audit. Your manifest.md line 89 attributes "R² approx 0.16 at female-range concentrations" to Cao 2017. The full text of that paper is in your library and it reports no R-squared value anywhere. It reports bias and coefficient of variation.

The number may well be real and from a different paper, since your sentence is specific (Beckman immunoassay, below 37.6 ng/dL), which is not the shape of an invented figure. But right now it's cited to a paper that doesn't contain it, and the claim appears in testosterone-women.md, in manifest.md, and in smartstrongalive-testosterone-women-part2.md line 85.

What Cao 2017 actually supports, and it's strong: 142 CLIA-certified labs, single-donor serum against CDC reference targets. On the female-range sample at 15.5 ng/dL, reported values ran from 7.1 to 39.8 ng/dL, 35% among-laboratory CV, per-lab bias from minus 55% to plus 156%. Four immunoassay platforms met none of the bias goals.

[Cao Z, Botelho JC, Rej R, Vesper H. *Clin Chim Acta.* 2017;469:31-36. doi:10.1016/j.cca.2017.03.010]

Recommended

Tell me where the R-squared figure came from and I'll verify it and fix the attribution in all three places. If you can't place it, the honest move is to drop it and lean on the Cao bias and CV numbers, which make the same argument with data you definitely hold.

5. The neuroprotection sentence

testosterone-ambition-manifesto.md line 84 · left untouched

Currently: "Some research suggests testosterone, alongside estrogen, may help defend the aging brain against the changes that lead to dementia."

I looked hard for support. It isn't there, and two high-quality sources contradict it. A 2025 systematic review and meta-analysis covering 1,016,055 participants states that no included study examined testosterone at all. The definitive RCT meta-analysis, 36 trials and 8,480 women, found no cognitive effect. And the 2019 Global Consensus you rely on elsewhere says explicitly there is insufficient evidence to use testosterone to delay cognitive decline. Publishing the sentence would put you in direct conflict with a source you cite two claims earlier.

[Melville M, et al. *Lancet Healthy Longev.* 2025;6(12):100803. doi:10.1016/j.lanhl.2025.100803]

[Islam RM, et al. *Lancet Diabetes Endocrinol.* 2019;7(10):754-766. doi:10.1016/S2213-8587(19)30189-5]

[Dratva MA, et al. *Biol Sex Differ.* 2024;15(1):47. doi:10.1186/s13293-024-00620-4]

Recommended

Replace with the narrow APOE4 version, which is defensible and personally stronger given you're APOE4 homozygous:

"In women who carry the APOE-e4 allele, lower testosterone has been linked to poorer memory and processing speed. That is an association in untreated women, not evidence that taking testosterone protects the brain. No trial has tested whether it does."

Two caveats on Dratva if you use it: 213 women, cross-sectional, no treatment involved, and its testosterone was measured on a multiplex immunoassay, which is the exact method your own measurement argument says is unreliable at female concentrations. You may prefer to just delete the sentence.

6. The dead link

anhedonia-testosterone-midlife.md line 243 · left untouched

"The Hormone Nobody Told You About" points at #, in the Part 2 tease you send readers to twice. Send me the real URL, or say the word and I'll remove the link and keep the text.

Two things I did without asking

The five habits are now a write-time rule. You asked how to stop these being written in the first place rather than caught afterward, so they're in your voice profile with explicit budgets: binary contrast zero, faux-insight frame zero, honesty announcement once per piece, reader-instruction once per piece, "actually" only where it marks real contrast. Your voice profile loads before any long-form drafting, so this now applies to every project, not just this site. The displacement rule goes with them: cutting a construction doesn't cut its rhythm, and the beat migrates into colon reveals and comma splices unless you rewrite the sentence properly.

Nine new sources are ready for your library, all CrossRef-verified today, none currently in manifest.md. Seven psychiatry-disparity papers plus two anhedonia-by-race papers worth keeping as counter-evidence so nobody re-litigates it. Say the word and I'll write the notes with status: stamped correctly at birth and pull full text where PMC has it.